Research ArticleDrug Discovery and Translational Medicine
The Dual Amylin and Calcitonin Receptor Agonist KBP-088 Induces Weight Loss and Improves Insulin Sensitivity Superior to Chronic Amylin Therapy
Anna Thorsø Larsen, Nina Sonne, Kim Vietz Andreassen, Kristoffer Gehring, Morten Asser Karsdal and Kim Henriksen
Journal of Pharmacology and Experimental Therapeutics July 2019, 370 (1) 35-43; DOI: https://doi.org/10.1124/jpet.119.257576
Anna Thorsø Larsen
Nordic Bioscience Biomarkers and Research, Department of Endocrinology, Herlev, Denmark
Nina Sonne
Nordic Bioscience Biomarkers and Research, Department of Endocrinology, Herlev, Denmark
Kim Vietz Andreassen
Nordic Bioscience Biomarkers and Research, Department of Endocrinology, Herlev, Denmark
Kristoffer Gehring
Nordic Bioscience Biomarkers and Research, Department of Endocrinology, Herlev, Denmark
Morten Asser Karsdal
Nordic Bioscience Biomarkers and Research, Department of Endocrinology, Herlev, Denmark
Kim Henriksen
Nordic Bioscience Biomarkers and Research, Department of Endocrinology, Herlev, Denmark
Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Research ArticleDrug Discovery and Translational Medicine
The DACRA KBP-088 Is Superior to Amylin Therapy
Anna Thorsø Larsen, Nina Sonne, Kim Vietz Andreassen, Kristoffer Gehring, Morten Asser Karsdal and Kim Henriksen
Journal of Pharmacology and Experimental Therapeutics July 1, 2019, 370 (1) 35-43; DOI: https://doi.org/10.1124/jpet.119.257576
Research ArticleDrug Discovery and Translational Medicine
The DACRA KBP-088 Is Superior to Amylin Therapy
Anna Thorsø Larsen, Nina Sonne, Kim Vietz Andreassen, Kristoffer Gehring, Morten Asser Karsdal and Kim Henriksen
Journal of Pharmacology and Experimental Therapeutics July 1, 2019, 370 (1) 35-43; DOI: https://doi.org/10.1124/jpet.119.257576
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement